Analysis of clinical use of drugs for lung cancer treatment in a hospital
10.12206/j.issn.2097-2024.202312076
- VernacularTitle:某院肺癌治疗药物临床使用情况分析
- Author:
Shuang LIU
1
;
Yanqiu WU
2
;
Hongbin YI
3
;
Liping KUAI
4
;
Dongyan XU
4
;
Jianhua TANG
5
Author Information
1. Department of Pharmacy, Children’s Hospital Affiliated to Zhengzhou University, Zhengzhou 450018, China.
2. Peking University People's Hospital, Beijing 100044, China.
3. School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China.
4. Science and Technology Development Center of Chinese Pharmaceutical Association, Beijing 100022, China.
5. Department of Pharmacy, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.
- Publication Type:Pharmacyadministration
- Keywords:
lung cancer;
defined daily doses;
medication cost;
defined daily dose cost
- From:
Journal of Pharmaceutical Practice and Service
2026;44(3):152-159
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare and analyze the changes in the use of lung cancer therapeutic drugs before and after the national initiation of health insurance negotiations, and to study the impact of a series of policies on the use of lung cancer drugs. Methods Descriptive statistical methods were used analyze the basic situation of lung cancer patients and the changes of corresponding therapeutic drugs in Peking University People's Hospital from 2014 to 2020, as well as to the hospital procurement data of lung cancer therapeutic drugs in the database of the Chinese Medicine Economic Information. Results From 2014 to 2020, the total cost per capita of lung cancer patients showed a trend of first increasing and then decreasing, increasing before the national drug negotiation and gradually decreasing after the negotiation. After 2017, the use of small ATC categories such as VEGF/VEGFR inhibitors and EGFR tyrosine kinase inhibitors increased significantly, along with a rise in the number of monoclonal antibody varieties. The DDDs of osimertinib, anlotinib, alectinib, crizotinib and other drugs in the medical insurance list increased significantly, and the average daily cost decreased significantly. Conclusion The number of hospitalization days for lung cancer patients had continued to shorten in recent years, and the structure of drug use had changed significantly. The adjustment of the medical insurance catalog had led to more innovative lung cancer drugs showing the trend of volume up and price down.
